Alessan­dro Ri­va takes over Trans­gene as As­traZeneca walks away from on­colyt­ic virus pact

As­traZeneca is bail­ing on its four-year on­colyt­ic virus part­ner­ship with French biotech Trans­gene, hand­ing back an in-li­censed pro­gram that’s been cleared to en­ter the clin­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER